Objective: To explore the effect of valproic acid, levetiracetam, oxcarbazepine on bone metabolism and quality of life in children.Methods: From January 2016 to June 2017,95 children with epileptic in Department of Pediatric,Cangzhou People's Hospital,were retrospectively analyzed,and were divided into VPA group, LEV group and OXC group according to antiepileptic drugs used, the three groups received treatment of valproic acid, levetiracetam, oxcarbazepine. Calcium, phosphorus, alkaline phosphatase, 25-(OH)D in serum and bone density of the three groups were compared before and after treatment, the occurrence of abnormal bone density was statistically and compared, usingverbal IQ(VIQ), performance IQ(PIQ),full scale IQ(FIQ) to evaluate the patients's neurocognitive status before and after treatment, the incidence of adverse reactions during the follow-up were statistically analyzed.Results: Serum calcium in VPA group decreased significantly after 1 year of treatment compared with before treatment(t=3.092,P=0.003), serum phosphorus in VPA group increased significantly after 1 year of treatment compared with before treatment(t=-4.939,P<0.001), alkaline phosphatase showed progressive increase after treatment(P<0.05), 25-(OH)Dand bone density decreased progressively after treatment(P<0.05).The incidence of abnormal bone densityin VPA group was significantly higher than that in the other two groups(Log rank χ2=8.568,7.430;P=0.003,0.006), the PIQ in VPA group was significantly decreased 1 year after treatment(t=18.348,P<0.001), the score of VIQ, PIQ, FIQ in LEV group were significantly increased 1 year after treatment(P<0.05). Conclusion: Levetiracetam has less effect on bone metabolism in children with epilepsy, it can also effectively improve neurocognitive ability quality of life.
 BRODIE M J,BESAG F,ETTINGER A B,et al. Epilepsy,antiepileptic drugs,and aggression:an evidence-based review[J].Pharmacol Rev,2016,68(3):563-602.
 KOSSOFF E H,ZUPEC-KANIA B A,AUVIN S,et al. Optimal clinical management of children receiving dietary therapies for epilepsy:updated recommendations of the International Ketogenic Diet Study Group[J].Epilepsia Open,2018,3(2):175-192.
 RAHIMDEL A,DEHGHAN A,MOGHADAM M A,et al.Relationship between bone density and biochemical markers of bone among two groups taking carbamazepine and sodium valproate for epilepsy in comparison with healthy individuals in Yazd[J].Electron Physician,2016,8(11):3257-3265.
 ZHANG Y,ZHENG Y X,ZHU J M,et al. Effects of antiepileptic drugs on bone mineral density and bone metabolism in children:a meta-analysis[J].J Zhejiang Univ Sci B,2015,16(7):611-621.
 SCHEFFER I E,BERKOVIC S,CAPOVILLA G,et al.ILAE classification of the epilepsies:position paper of the ILAE Commission for Classification and Terminology[J].Epilepsia,2017,58(4):512-521.
 ILI V,BOGIEVI D,MILJKOVI B,et al.Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy[J].Epileptic Disord,2016,18(2):181-186.
 KOO D L,JOO E Y,KIM D,et al.Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy[J].Epilepsy Res,2013,104(1-2):134-139.
 WEIJENBERG A,BROUWER O F,CALLENBACH P M.Levetiracetam monotherapy in children with epilepsy:a systematic review[J].CNS Drugs,2015,29(5):371-382.
 BAUER S,HOFBAUER L C,RAUNER M, et al.Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED)-a prospective multicenter study[J].Epilepsy Res,2013,106(3):417-422.
 BREUER L,GREVERS E,BOON P,et al.Cognitive deterioration in adult epilepsy:clinical characteristics of "Accelerated Cognitive Ageing"[J].Acta Neurol Scand,2017,136(1):47-53.